Introduction
Dysphagia is a major symptom in patients with a malignant esophageal stricture, such
as esophageal carcinoma, gastroesophageal junction carcinoma, gastric cardia carcinoma,
and esophageal metastasis from other carcinomas, and it causes poor nutrition intake
and a decrease in quality of life. Esophageal self-expandable metal stent (SEMS) placement
has been widely used for palliative treatment of unresectable malignant esophageal
strictures to relieve dysphagia and increase nutritional intake [1]
[2]
[3]. Recently, a clinical guideline for esophageal stents was published by the European
Society of Gastrointestinal Endoscopy (ESGE) [4]. In this guideline, ESGE recommended placement of a partially or fully covered SEMS
for palliative treatment of malignant dysphagia over laser therapy, photodynamic therapy,
and esophageal bypass. However, migration is one of the most common adverse events
(AE) after SEMS placement, and its prevalence ranges from 4 – 36 % [2]
[3]
[5]
[6]
[7]. Several researchers have reported fully covered stent placement, concurrent chemotherapy
and/or radiotherapy and stents placed across the gastroesophageal junction as factors
that increase risk of stent migration [5]
[6]
[8]
[9]. Additionally, the general indication of esophageal SEMS placement for unresectable
malignant esophageal stricture is severe dysphagia in cases in which the stricture
cannot allow the passage of a standard peroral endoscope to prevent migration [3]
[8]. However, in clinical practice, we have often encountered malignant esophageal strictures
in patients with severe dysphagia; however, the stricture is often mild and can allow
the passage of a standard peroral endoscope. In such mild stenosis cases with severe
dysplasia, we face the problem regarding the suitable timing of stent placement because
of the risk of migration.
Recently, a new endoscopic clipping device called the over-the-scope-clip (OTSC) system
(Ovesco Endoscopy, Tübingen, Germany) has become available for the closure of perforations,
anastomotic leaks, and fistulas [10]
[11]. The OTSC system has a stronger closing force than the through-the-scope hemostatic
clip [12]. Therefore, some researchers have reported esophageal SEMS fixation with an OTSC
to prevent migration [10]
[11]
[12]
[13]. However, in these reports, the main indications for stenting were postoperative
leak, fistula, perforation and benign strictures. Few reports have discussed efficacy
or safety of esophageal SEMS fixation with an OTSC for malignant esophageal strictures.
Therefore, we performed a study on the feasibility of esophageal SEMS fixation with
an OTSC for malignant esophageal strictures.
Patients and methods
Patients
Twelve consecutive patients underwent esophageal SEMS placement and fixation with
an OTSC for malignant esophageal strictures and 13 procedures were performed at Fukushima
Medical University Hospital between September 2014 and October 2016. Procedural and
clinical data were collected and analyzed retrospectively from a prospectively maintained
endoscopy database. The inclusion criteria for patients for SEMS placement were as
follows: 1) dysphagia and a dysphagia score of at least 2 (dysphagia scores: 0, no
dysphagia; 1, dysphagia to normal solid food; 2, dysphagia to soft solid foods; 3,
dysphagia also with liquids; and 4, aphagia, inability to swallow saliva) [14]; 2) presence of a malignant esophageal stricture that did not allow passage of the
endoscope, which had a diameter of 9.2 mm (GIF-Q260; Olympus Medical Systems Corp.,
Tokyo, Japan), or could barely allow the passage of the scope; 3) ineligibility for
curative surgery because of advanced or metastatic disease or poor functional status;
and 4) lack of exposure to initial chemotherapy and/or radiotherapy. The exclusion
criteria were as follows: 1) a stricture within 2 cm from the upper esophageal sphincter;
2) radiotherapy or chemotherapy within 1 month prior to SEMS placement; and 3) refusal
to undergo SEMS placement and fixation with an OTSC. SEMS fixation with an OTSC was
performed in all SEMS placement patients who consented to use the OTSC in this study
period. All patients provided written informed consent before the procedure, and this
study was conducted with the approval of the Ethics Committee of Fukushima Medical
University (approval No. 2496).
SEMS placement and fixation with an OTSC
All procedures were performed with patients under deep sedation using midazolam. The
lesion was inspected with an endoscope (GIF-Q260, GIF-Q260 J, GIF-2T240; Olympus Medical
Systems Corp., Tokyo, Japan) to determine the location and length of the stenosis.
Marking clips were placed with endoscopy at the upper end of the stricture. In mild
stricture cases that allowed the passage of the endoscope, marking clips were also
placed in the lower end. A stent that was at least 4 cm longer than the stricture
was used to allow at least a 2-cm extension above and below the proximal and distal
tumor margins. The stent was positioned over a guidewire and deployed under fluoroscopy
guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC
system was loaded onto the scope and part of the upper rim of the stent was suctioned
into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal
wall ( [Fig. 1]). We avoided deploying the OTSC in areas of pulsations to prevent potential grasping
of the vasculature structure, as noted in a previous report [12]. Only a single OTSC was placed per patient. In all cases, the Niti-S stent (Taewoong
Medical, Seoul, Korea) was used and the type of stents were as follows: a long, covered
stent (n = 10), partially covered stent (n = 2), and fully covered stent (n = 1),
with diameters of 18 mm and lengths of 80 to 150 mm. The type of OTSC was 11/6 t,
which had an OTSC cap diameter of 16.5 mm and clip width of 9 mm, and the type of
teeth was ‘t’ in all cases.
Fig. 1 a An endoscopic image. The over-the-scope-clip (OTSC) system was loaded onto the scope,
and part of the upper rim of the stent was suctioned into the transparent cap before
releasing the OTSC. b An endoscopic image. The OTSC was released, grasping both the self-expandable metal
stent and esophageal wall. c An X-ray image after the OTSC and stent placement.
Outcomes
The primary endpoint was technical success. The secondary endpoints were clinical
success, changes in the dysphagia score from before SEMS placement to 1 week after
SEMS placement, and adverse events (AE), including migration. Technical success was
defined as adequate deployment and positioning of the SEMS at the site of the stricture
and ability to deploy the OTSC and fix the SEMS. Clinical success was defined as an
improvement of at least 1 grade in the dysphagia score 1 week after SEMS placement.
Stent migration was defined as movement out of the stricture, which was diagnosed
on endoscopy and radiography. Follow-up information after SEMS placement was collected
from medical records. If patients were followed up outside of our institution, we
conducted a questionnaire survey with their primary care physicians. The procedure
time required for OTSC placement was calculated from endoscope insertion after SEMS
deployment to final endoscope withdrawal after OTSC placement.
Statistical analysis
Values are reported as the medians with ranges. Changes in dysphagia scores from before
SEMS placement to 1 week after SEMS placement were analyzed using the Wilcoxon’s signed-rank
test. Differences were considered to be significant at P < 0.05. This analysis was performed using the SPSS software (version 21 for windows;
IBM Corp, Armonk, NY, USA).
Results
Patient characteristics are summarized in [Table1]. The median age of the patients (10 men, 2 women) was 70 years (range 48 – 83 years).
The source of malignant esophageal stricture included esophageal carcinoma in 10 patients
(5 squamous cell carcinoma, 3 adenocarcinoma, 1 adenosquamous cell carcinoma, and
1 endocrine cell carcinoma), gastroesophageal junction carcinoma in one patient, and
lymph node metastasis of lung carcinoma in 1 patient. Before SEMS placement, 5 patients
had received chemoradiotherapy, 4 patients had received only chemotherapy, and 3 patients
had received only the best supportive care. The median period from last chemotherapy
to SEMS placement in chemoradiotherapy or chemotherapy cases was 1 month (range 1 – 23
months). The main locations of the strictures were the lower esophagus in 9 patients
and middle esophagus in 3 patients. In 6 patients (7 SEMS placements), the stricture
allowed passage of the endoscope, which had a diameter of 9.2 mm (GIF-Q260; Olympus
Medical Systems Corp., Tokyo, Japan) before SEMS placement.
Table 1
Patient characteristics.
Case
|
Age
|
Gender
|
Source of malignant
esophageal stricture
|
Location
|
Passage of
GIF-Q260
|
DS before SEMS placement
|
Pretreatment
|
1
|
70
|
Male
|
Esophageal squamous cell carcinoma
|
Middle
|
Impossible
|
4
|
Chemoradiotherapy
|
2
|
79
|
Male
|
Esophageal adenocarcinoma
|
Lower
|
Possible
|
3
|
Chemotherapy
|
3
|
57
|
Male
|
Esophageal endocrine cell carcinoma
|
Lower
|
Impossible
|
3
|
Chemotherapy
|
4
|
52
|
Male
|
Lymph node metastasis of lung carcinoma
|
Middle
|
Impossible
|
3
|
Chemoradiotherapy
|
5
|
77
|
Female
|
Esophageal adenosquamous cell carcinoma
|
Lower
|
Possible
|
4
|
None
|
6
|
53
|
Female
|
Gastroesophageal junction carcinoma
|
Lower
|
Possible
|
4
|
Chemotherapy
|
7
|
48
|
Male
|
Esophageal adenocarcinoma
|
Lower
|
Impossible
|
2
|
Chemotherapy
|
8
|
83
|
Male
|
Esophageal squamous cell carcinoma
|
Lower
|
Impossible
|
2
|
None
|
9
|
75
|
Male
|
Esophageal squamous cell carcinoma
|
Middle
|
Possible
|
2
|
Chemoradiotherapy
|
10
|
84
|
Male
|
Esophageal adenocarcinoma
|
Lower
|
Impossible
|
3
|
None
|
11
|
67
|
Male
|
Esophageal squamous cell carcinoma
|
Lower
|
Possible
|
2
|
Chemoradiotherapy
|
12
|
74
|
Male
|
Esophageal squamous cell carcinoma
|
Lower
|
Possible
|
2
|
Chemoradiotherapy
|
Location: middle, middle esophagus; lower, lower esophagus
DS, dysphagia score; SEMS, self-expandable metal stent
Treatment outcomes and AEs are summarized in [Table 2]. The technical success rate was 100 % (12/12), and successful application of the
OTSC was accomplished in all patients and all SEMS placements. Median procedure time
required for OTSC placement was 11 minutes (range 6 – 15 minutes). The clinical success
rate was 92.3 % (11/12), and 11 patients showed an improved dysphagia score after
SEMS placement. Only 1 patient did not improve clinically. Median dysphagia score
before and at 1 week after SEMS placement was 3 (range 2 – 4) and 0 (0 – 4), respectively,
which indicated improvement at 1 week after SEMS placement compared with before SEMS
placement (P = 0.002). Furthermore, in mild stricture cases that allowed passage of a GIF Q260
endoscope, median dysphagia score before and at 1 week after SEMS placement was 3
(range 2 – 4) and 0 (0 – 4), respectively, which also indicated improvement at 1 week
after SEMS placement compared with before SEMS placement (P = 0.026).
Table 2
Treatment outcomes and adverse events.
Case
|
Technical success
|
Clinical success
|
Procedure time for OTSC placement, min
|
Type of SEMS
|
Length of SEMS, mm
|
DS after SEMS placement
|
Adverse
events
|
Concurrent chemotherapy
|
1
|
Yes
|
Yes
|
11
|
Partially covered
|
80
|
0
|
None
|
No
|
2
|
Yes
|
Yes
|
12
|
Long covered
|
120
|
0
|
None
|
No
|
3 – 1
|
Yes
|
Yes
|
10
|
Long covered
|
100
|
0
|
None
|
Yes
|
3 – 2
|
Yes
|
Yes
|
15
|
Long covered
|
100
|
0
|
None
|
No
|
4
|
Yes
|
Yes
|
9
|
Partially covered
|
100
|
1
|
None
|
No
|
5
|
Yes
|
No
|
11
|
Long covered
|
150
|
4
|
None
|
No
|
6
|
Yes
|
Yes
|
8
|
Long covered
|
80
|
0
|
None
|
Yes
|
7
|
Yes
|
Yes
|
12
|
Long covered
|
100
|
1
|
None
|
No
|
8
|
Yes
|
Yes
|
13
|
Long covered
|
120
|
0
|
None
|
No
|
9
|
Yes
|
Yes
|
13
|
Fully covered
|
80
|
0
|
None
|
Yes
|
10
|
Yes
|
Yes
|
9
|
Long covered
|
80
|
0
|
None
|
No
|
11
|
Yes
|
Yes
|
8
|
Long covered
|
150
|
0
|
None
|
No
|
12
|
Yes
|
Yes
|
6
|
Long covered
|
120
|
0
|
None
|
No
|
OTSC, over-the-scope-clip; DS, dysphagia score; SEMS, self-expandable metal stent
There were no AEs associated with the placement of the SEMS and the deployment of
the OTSC. After SEMS placement and OTSC deployment, 4 patients required analgesic
agents, such as acetaminophen, for mild chest pain. All 4 patients were able to tolerate
pain after medication and did not require any analgesic agents during the following
days. The median clinical follow-up period after SEMS placement was 2 months (range
1 – 12). Three patients underwent chemotherapy and 9 patients received the best supportive
care. Nine patients died of their underlying carcinoma. Recurrence of dysphagia occurred
in 1 patient. In this case, SEMS placement with an OTSC was performed twice. The initial
OTSC and SEMS were removed 12 months after the first SEMS placement because of obstruction
by a tumor, and another SEMS was placed with an OTSC. OTSC removal was safely performed
using a snare and gripping forceps. No delayed AEs, including migration of the SEMS, were observed during the follow-up
period.
Discussion
This study showed that SEMS placement and fixation with an OTSC for malignant esophageal
strictures was successful in all cases and that 92.3 % of the patients had an improved
dysphagia score. There were no AEs. In particular, there were no SEMS migrations.
Nevertheless, a SEMS placed across the gastroesophageal junction because of stricture
of the lower esophagus, mild stricture cases, a fully covered stent, and patients
who underwent chemotherapy after SEMS placement, which were reported as the risk factors
for SEMS migration, were included [5]
[6]
[8]
[9].
According to the ESGE guideline [4], SEMS placement has not been recommended as a bridge to surgery, during concurrent
use of radiotherapy, or prior to preoperative chemoradiotherapy, which has been associated
with a high incidence of AEs. Our indications agreed with this guideline. The ESGE
guideline described the controversy over whether SEMS placement after chemoradiotherapy
is associated with the risk of major AEs; however, some studies have shown an increased
risk of AEs. Therefore, we specifically informed patients who underwent chemoradiotherapy
of the fatal AE risk of SEMS placement before the procedure.
Some techniques for SEMS fixation have been reported to prevent migration. Shim et
al. [15] reported a technique consisting of a modified stent that was designed with a silk
thread attached to the edge of the proximal end of the stent. Because this stent may
not be routinely available, modifications of this technique using dental floss have
also been reported [16]. With these techniques, after SEMS placement, the silk thread or dental floss is
fixed to the patient’s earlobe or nose, and the external fixation is removed at least
2 weeks after the procedure. Several researchers have reported the efficacy of SEMS
fixation with through-the-scope hemostatic clips [17]
[18]. They have shown that rates of SEMS migration range from 0 % – 13 %. However, the
authors fixed the SEMS by using 2 to 4 hemoclips because of the limited opening widths,
closure strengths, and depths of penetration [12]. Recently, new SEMS fixation techniques using an OTSC, which is a new endoscopic
clipping device that has a strong force, have been reported [10]
[11]
[12]
[13]. The main indications for stenting in these reports were benign diseases, such as
postoperative leak, fistula, perforation and benign strictures. In these reports,
OTSC application was successful in all patients. Irani et al. [12] and Mudumbi et al. [13] reported that SEMS migration occurred in 15.4 % and 16.7 % of patients, respectively,
in SEMS fixed with an OTSC for benign esophageal strictures.
In our study, successful application of the OTSC was accomplished in all cases, as
found in previous reports. SEMS fixed with an OTSC was easily and rapidly accomplished
because an OTSC is easily placed by attaching it to the upper rim of the SEMS and
esophageal wall as an endoscopic variceal ligation, and only a single OTSC was placed
per patient. SEMS fixed with an OTSC was performed safely in all cases, and there
were no SEMS migrations of the malignant esophageal strictures. Of the 6 mild stricture
cases (7 SEMS placements) whose stricture allowed the passage of the endoscope, which
had a diameter of 9.2 mm, 5 cases (6 SEMS placements) showed improved dysphagia scores,
indicating their improved quality of life. Only 1 case of esophageal adenosquamous
carcinoma, which extensively invaded the stomach, did not improve clinically. However,
even with a mild stricture, if a patient suffers from severe dysphagia, SEMS placement
for a malignant esophageal stricture and fixation with an OTSC to prevent migration
may help improve quality of life. Additionally, in mild stricture cases, it is possible
to place marking clips in the lower end of the stricture, which may be useful for
determining a suitable position for a SEMS.
Recently, Reijm et al. [19] reported that SEMS for malignant esophageal stricture results in moderate to severe
pain, which is probably related to the instant expansion of SEMS, in 60 % of patients
after SEMS placement. In this study, chest pain requiring analgesic agents after the
procedure was observed in 4 patients (33.3 %); however, no severe pain was observed.
We considered the pain to be related to expansion of the SEMS, not grasping the esophageal
wall with the OTSC, because the pain gradually decreased over time, similar to a previous
report [19].
In the 1 case of recurrence of dysphagia, OTSC removal was safely performed using
a snare and gripping forceps. Several researchers have also described a method for
OTSC removal by cutting the hinge using argon plasm coagulation at 90 to 100 W [12]
[20]. Another researcher also described a method that uses an injector needle to create
a submucosal cushion below the OTSC followed by use of a needle knife or exposed tip
of a snare to make an incision below the OTSC into the submucosal cushion [13].
In this study, a fully covered stent was used in only 1 middle esophageal stricture
case. Long covered stents were used in 10 procedures across the gastroesophageal junction
to prevent gastroesophageal reflux. Partially covered stents were used in 2 cases
of middle esophageal stricture to sufficiently grasp the upper rim of the stent using
the OTSC because the upper rim of the partially covered stent was bare and was an
uncovered region. In terms of the effect of fixation with an OTSC with a fully covered
stent that does not have an uncovered lesion, additional studies are necessary.
This study has some limitations. First, it was small, had a retrospective design and
was conducted at a single institution. Second, we did not compare the outcomes between
fixation in the OTSC group and non-fixation group. Third, it remains unclear whether
OTSC removal is both possible and safe at any time because reports on OTSC removal
comprise small sample sizes [12]
[13]
[20]. Further prospective studies are necessary to confirm the effect of fixation with
an OTSC. Finally, OTSC costs 79,800 Japanese yen (= approximately 720 US dollars),
which makes it very expensive.
Conclusions
In conclusion, SEMS fixation with an OTSC to prevent migration for malignant esophageal
strictures is feasible, safe, and easy. Further additional studies are necessary to
confirm the effect of fixation with an OTSC.